Dr. Jayne E. Hastedt has over 35 years of experience in pharmaceutical product development. She has had management and technical leadership responsibilities for the development of small molecules, peptides, and proteins using various dosage forms, routes of delivery, and technologies and has supported successful US and European regulatory product approvals. Her experience includes leading physicochemical characterization and CMC development activities spanning early drug product development through product registration and launch as well as life cycle management. She has supported the development of oral, transdermal, oral controlled release dosage forms, and specializes in inhaled drug delivery product development. She is currently co-leading an initiative within the PQRI BTC to develop an inhalation-based Biopharmaceutics Classification System (iBCS) for inhaled drugs. Dr. Hastedt is the Managing Director of JDP Pharma Consulting, LLC and throughout her career, she has had the opportunity to work at Johnson & Johnson/ALZA, Inhale, Glaxo/Glaxo Wellcome, and Boehringer Ingelheim. She received her MS and PhD degrees from the University of Wisconsin – Madison School of Pharmacy under the guidance of Professors James L. Wright and George Zografi. She holds adjunct faculty positions at the UW School of Pharmacy in the Pharmacy Professional Development Division and the University of the Pacific Thomas Long School of Pharmacy and Health Sciences. Dr. Hastedt has had the opportunity to support the June Land O’Lakes Conferences for many years and chaired the conference multiple times. She recently collaborated with the Division of Pharmacy Professional Development to design and launch an online graduate level Pharm Sci 750 course on The Drug Development Process in 2020. In 2021, she received an Honorary Citation of Merit from the University of Wisconsin-Madison for her contributions to the field of Pharmacy.